To update our shareholders on the recent developments and to describe this round of fundraising, PBI held a Shareholders Dinner Meeting on January 9, 2022, at B1 Huaxi Yuan of Shangri-La’s Far Eastern, Taipei. There were 21 Shareholders and Representatives, as well as 15 Guests of Honor, making a total attendance of 41. The event started at 6:05 PM as scheduled.
PBI’s Founder Professor T.-C. Wu gave an opening speech by briefly reviewing PBI’s history and introducing our recent changes, including the hiring of Dr. M. Joe Ma as PBI’s new CEO in March of 2021.
This was followed by Dr. Ma’s presentaton of current status and future plans for PBI’s two pipeline products under development – PVX2 and PVX7. Dr. Ma shared the exciting preliminary results of PVX2’s ongoing phase II clinical trial, and laid out our plans to complete phase II clinical trials of both products in the next 2-3 years. He clearly outlined the goal of IPO in Taiwan in 2024. The budget of these plans was presented, and the details of this A round of fundraising were described.
Last, President Lily Wu gave an inspiring remark before the dinner was served. Guests and Shareholders alike were excited by the presentation and interacted with PBI leaders freely. The dinner concluded at around 09:30 PM.
